ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0064

Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study

Baptiste Chevet1, Gabriel Figueroa Parra1, Jeffrey X. Yang1, Mehmet Hocaoglu1, Shirley-Ann Osei-Onomah1, Cassondra Hulshizer1, Tina Gunderson1, Divi CORNEC2, Cynthia Crowson3 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2CHRU Brest, Brest, France, 3Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2022

Keywords: Access to care, Cardiovascular, Health Care, prevention, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a disease that can damage multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular disease, diabetes, osteoporosis, and infections. Preventive services are essential in patients with SLE to mitigate the risks mentioned above. We aimed to evaluate the trends of preventive services utilization in patients with systemic lupus erythematosus compared with the non-SLE population.

Methods: All ≥19-year-old patients with SLE in a population-based cohort on January 1, 2015, were included and matched (1:1) by sex, age, race, and county to non-SLE comparators. Patients with SLE and comparators were followed until February 29, 2020 (due to the beginning of restrictions secondary to the SARS-CoV-2 pandemic), emigration, or death. We evaluated breast and cervical cancer, cardiovascular disease, diabetes mellitus, and osteoporosis screening based on the US Preventive Services Task Force recommendations in effect during 2015-2020. Seasonal influenza, pneumococcal, and herpes zoster vaccination were evaluated following the current recommendations made by the Advisory Committee on Immunization Practices from the Centers for Disease Control and Prevention in the US during the same period. Among both groups, we compared the rates of screenings for breast and cervical cancer, hypertension, hyperlipidemia, diabetes mellitus, osteoporosis, and immunizations. The cumulative incidence was estimated using Aalen-Johansen methods. Cox proportional hazards models with adjustment for age, sex, and race were used to compare screening tests and vaccination rates between the two groups.

Results: We included 440 SLE patients and 430 non-SLE comparators. The trends of provided preventive services in patients with and without SLE are depicted in Table 1. The probability of breast cancer screening among women with SLE was similar to comparators (hazard ratio [HR] 1.09, 95% CI 0.85-1.39, Figure 1A), while cervical cancer screening was lower (HR 0.75, 95% CI 0.58-0.96, Figure 1B). Hypertension screening was higher among patients with SLE (HR 1.35, 95% CI 1.13-1.62, Figure 1C); however, hyperlipidemia screening was similar to comparators (HR 1.16, 95% CI 0.96-1.41, Figure 1D). Diabetes and osteoporosis screenings were more likely to be performed for SLE patients than for comparators (HR 2.46, 95% CI 2.11-2.87, Figure 1E; and HR 3.19, 95% CI 2.31-4.41, Figure 1F; respectively). The trends of vaccine uptake in both groups are depicted in Table 2. Influenza and pneumococcal immunizations were higher among SLE patients (HR 1.31, 95% CI 1.12-1.54; and HR 2.06, 95% CI 1.38-3.09; respectively), while zoster vaccination was similar (HR 1.17, 95% CI 0.81-1.69) than comparators.

Conclusion: The trends of utilization of preventive services by SLE patients vary according to screening or vaccine compared with the general population. Considering the increased risk in this population, we demonstrate an opportunity for improvement, particularly in cervical cancer, hyperlipidemia, and osteoporosis screenings and vaccinations.

Supporting image 1

Table 1. Trends of provided preventive services in patients with and without systemic lupus erythematosus (SLE) in the Lupus Midwest Network cohort between 2015 and 2020.

Supporting image 2

Table 2. Trends of vaccine uptake in patients with and without systemic lupus erythematosus (SLE) in the Lupus Midwest Network cohort between 2015 and 2020.

Supporting image 3

Figure 1. Trends and probability of receiving preventive services among systemic lupus erythematosus patients (purple line) and their comparators (green line) in the Lupus Midwest Network registry. Cumulative incidence of A) breast cancer screening by mammograms; B) cervical cancer screening with Pap smear or HPV test; C) hypertension screening by office blood pressure assessment; D) hyperlipidemia screening by blood lipids testing; E) diabetes mellitus screening by blood glucose testing and F) osteoporosis screening by DXA. Hazard ratios were adjusted for age, sex, and race; those for breast and cervical cancer were adjusted for age and race.


Disclosures: B. Chevet, None; G. Figueroa Parra, None; J. Yang, None; M. Hocaoglu, None; S. Osei-Onomah, None; C. Hulshizer, None; T. Gunderson, None; D. CORNEC, None; C. Crowson, None; A. Duarte-Garcia, None.

To cite this abstract in AMA style:

Chevet B, Figueroa Parra G, Yang J, Hocaoglu M, Osei-Onomah S, Hulshizer C, Gunderson T, CORNEC D, Crowson C, Duarte-Garcia A. Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/utilization-of-preventive-services-in-a-systemic-lupus-erythematosus-population-based-cohort-a-lupus-midwest-network-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utilization-of-preventive-services-in-a-systemic-lupus-erythematosus-population-based-cohort-a-lupus-midwest-network-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology